Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey
AIMS: To evaluate the cost-effectiveness of standard-of-care treatment (SoC) to SoC in combination with omalizumab (OML + Soc) in patients with severe asthma using real-world prospective clinical data from four major medical centers in Turkey.
MATERIALS AND METHODS: Between February 2018 and November 2019, a total of 206 patients with severe asthma, including 126 of whom were in the OML + SoC group and 80 in the SoC group, were followed for 12 months to evaluate their asthma status and quality of life. Cost data for this patient-level economic evaluation were sourced from the MEDULA database of the hospitals and expressed in Turkish Lira (₺). Efficacy data were obtained by means of Turkish versions of the Asthma Control Test for asthma status, the 5-level EQ-5D-5L version (EQ-5D-5L), and the Asthma Quality of Life Scale for quality of life. A Markov model with 2-week cycles was specified, comparing costs and treatment effects of SoC vs. OML + SoC over a lifetime from the Turkish payer perspective.
RESULTS: Per-patient costs were ₺23,607.08 in the SoC arm and ₺425,329.81 in the OML + Soc arm, for a difference of ₺401,722.74. Life years (LY) and quality-adjusted life years (QALY) were 13.60 and 10.08, respectively, in the SoC group; and 21.26 and 13.35, respectively, in the OML + SoC group, for differences of 7.66 LYs and 3.27 QALYs. This yielded an incremental cost-effectiveness ratio of an additional ₺52,427.04 to gain 1 LY and an incremental cost-utility ratio of an incremental ₺122,675.57 to gain 1 QALY; the latter being below the ₺156,948 willingness-to-pay threshold for Turkey referenced by WHO. One-way and multivariate sensitivity analyses confirmed the base-case results.
CONCLUSION: Whereas most economic evaluations are based on aggregate data, this independent cost-effectiveness analysis using prospective real-world patient-level data suggests that omalizumab in combination with standard of care is cost-effective for severe asthma from the Turkish public payer perspective.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Journal of medical economics - 26(2023), 1 vom: 06. Jan., Seite 720-730 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tugay, Deniz [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2P471X1Z11 |
|---|
| Anmerkungen: |
Date Completed 25.05.2023 Date Revised 25.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/13696998.2023.2209417 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356332128 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356332128 | ||
| 003 | DE-627 | ||
| 005 | 20231226070232.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13696998.2023.2209417 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356332128 | ||
| 035 | |a (NLM)37129881 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tugay, Deniz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.05.2023 | ||
| 500 | |a Date Revised 25.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIMS: To evaluate the cost-effectiveness of standard-of-care treatment (SoC) to SoC in combination with omalizumab (OML + Soc) in patients with severe asthma using real-world prospective clinical data from four major medical centers in Turkey | ||
| 520 | |a MATERIALS AND METHODS: Between February 2018 and November 2019, a total of 206 patients with severe asthma, including 126 of whom were in the OML + SoC group and 80 in the SoC group, were followed for 12 months to evaluate their asthma status and quality of life. Cost data for this patient-level economic evaluation were sourced from the MEDULA database of the hospitals and expressed in Turkish Lira (₺). Efficacy data were obtained by means of Turkish versions of the Asthma Control Test for asthma status, the 5-level EQ-5D-5L version (EQ-5D-5L), and the Asthma Quality of Life Scale for quality of life. A Markov model with 2-week cycles was specified, comparing costs and treatment effects of SoC vs. OML + SoC over a lifetime from the Turkish payer perspective | ||
| 520 | |a RESULTS: Per-patient costs were ₺23,607.08 in the SoC arm and ₺425,329.81 in the OML + Soc arm, for a difference of ₺401,722.74. Life years (LY) and quality-adjusted life years (QALY) were 13.60 and 10.08, respectively, in the SoC group; and 21.26 and 13.35, respectively, in the OML + SoC group, for differences of 7.66 LYs and 3.27 QALYs. This yielded an incremental cost-effectiveness ratio of an additional ₺52,427.04 to gain 1 LY and an incremental cost-utility ratio of an incremental ₺122,675.57 to gain 1 QALY; the latter being below the ₺156,948 willingness-to-pay threshold for Turkey referenced by WHO. One-way and multivariate sensitivity analyses confirmed the base-case results | ||
| 520 | |a CONCLUSION: Whereas most economic evaluations are based on aggregate data, this independent cost-effectiveness analysis using prospective real-world patient-level data suggests that omalizumab in combination with standard of care is cost-effective for severe asthma from the Turkish public payer perspective | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a C1 | |
| 650 | 4 | |a C15 | |
| 650 | 4 | |a I | |
| 650 | 4 | |a I1 | |
| 650 | 4 | |a I19 | |
| 650 | 4 | |a Severe asthma | |
| 650 | 4 | |a cost-effectiveness analysis | |
| 650 | 4 | |a omalizumab | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a real-world data | |
| 650 | 7 | |a Omalizumab |2 NLM | |
| 650 | 7 | |a 2P471X1Z11 |2 NLM | |
| 700 | 1 | |a Top, Mehmet |e verfasserin |4 aut | |
| 700 | 1 | |a Aydin, Ömür |e verfasserin |4 aut | |
| 700 | 1 | |a Bavbek, Sevim |e verfasserin |4 aut | |
| 700 | 1 | |a Damadoğlu, Ebru |e verfasserin |4 aut | |
| 700 | 1 | |a Öner Erkekol, Ferda |e verfasserin |4 aut | |
| 700 | 1 | |a Koca Kalkan, Ilkay |e verfasserin |4 aut | |
| 700 | 1 | |a Kalyoncu, A Fuat |e verfasserin |4 aut | |
| 700 | 1 | |a Karakaya, Gül |e verfasserin |4 aut | |
| 700 | 1 | |a Oğuzülgen, I Kivilcim |e verfasserin |4 aut | |
| 700 | 1 | |a Türktaş, Haluk |e verfasserin |4 aut | |
| 700 | 1 | |a Abraham, Ivo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical economics |d 1999 |g 26(2023), 1 vom: 06. Jan., Seite 720-730 |w (DE-627)NLM098274902 |x 1941-837X |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:1 |g day:06 |g month:01 |g pages:720-730 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13696998.2023.2209417 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 1 |b 06 |c 01 |h 720-730 | ||